MedTrace Logo

Does Dual Therapy Hasten Antidepressant Response?

NCT00519428 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 245

Last updated 2017-10-04

Study results available
· View outcomes & findings →

Summary

This study will utilize a randomized double-blind design to evaluate whether initial treatment with two anti-depressant medications (escitalopram and bupropion) results in more rapid remission and greater over-all remission rates than either monotherapy in 240 depressed subjects.

Conditions

Interventions

DRUG

escitalopram

10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted

DRUG

bupropion extra long (XL)

150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted

DRUG

escitalopram + bupropion

same dosing schedule as for monotherapy

Sponsors & Collaborators

  • University of Ottawa

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • New York State Psychiatric Institute

    lead OTHER

Principal Investigators

  • Jonathan W. Stewart, M.D. · New York State Psychiatric Institute

  • Pierre Blier, M.D. · University of Ottawa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-07-31
Completion
2012-03-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00519428 on ClinicalTrials.gov